Share Price and Basic Stock Data
Last Updated: November 7, 2025, 6:23 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
ANG Lifesciences India Ltd operates in the pharmaceutical sector, with a current share price of ₹32.7 and a market capitalization of ₹42.7 Cr. The company has recorded fluctuating revenue trends over the last few years. Sales stood at ₹206.82 Cr for the fiscal year ending March 2023, a significant decline from ₹348.52 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue is reported at ₹98.27 Cr, indicating ongoing struggles in maintaining sales momentum. Quarterly sales data reveals a downward trajectory, with the June 2022 figure of ₹71.56 Cr declining to ₹29.58 Cr by September 2023. The most recent quarter ending March 2024 recorded a slight recovery with sales rising to ₹34.08 Cr. The company’s ability to navigate market challenges will be critical for future growth, especially in a competitive sector where innovation and product pipeline strength are essential.
Profitability and Efficiency Metrics
Profitability metrics for ANG Lifesciences indicate a challenging operational environment. The company reported a net profit of ₹-0.66 Cr for the fiscal year ending March 2023, declining further to ₹-10.34 Cr in March 2025. Operating profit margins (OPM) have shown volatility, with a negative OPM of -1.14% for March 2025, a stark contrast to the impressive 18.81% recorded in March 2022. The interest coverage ratio (ICR) stands at -0.02x, highlighting significant challenges in covering interest expenses. The return on equity (ROE) is reported at 13.8%, while the return on capital employed (ROCE) has plunged to -3.54%, indicating inefficiencies in utilizing capital effectively. The cash conversion cycle (CCC) has also risen to 158.34 days, suggesting potential liquidity issues that could hinder operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of ANG Lifesciences reflects a precarious financial position with total borrowings recorded at ₹70.58 Cr against reserves of ₹53.75 Cr. The debt-to-equity ratio stands at 1.26, indicating a reliance on debt financing, which is higher than typical industry norms. The company’s book value per share has significantly declined to ₹48.99 as of March 2025, down from ₹80.81 in March 2022. The price-to-book value (P/BV) ratio is currently at 0.46x, suggesting that the stock may be undervalued compared to its book value. Furthermore, the current ratio is reported at 1.15, reflecting a marginally healthy liquidity position, although the quick ratio of 0.77 indicates potential short-term liquidity concerns. These ratios underscore the need for strategic financial management to bolster the company’s balance sheet.
Shareholding Pattern and Investor Confidence
The shareholding structure of ANG Lifesciences reveals a strong promoter presence, with promoters holding 70.60% of the total shares as of March 2025. This indicates a stable control over the company, which can be a positive signal for investors. The public shareholding stands at 29.40%, with a total of approximately 6,400 shareholders. Over the past quarters, the number of shareholders has seen a gradual decline from 7,163 in March 2023 to the current figure, suggesting a potential waning interest among retail investors. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises concerns about broader market confidence. Maintaining investor trust will be crucial as the company navigates its current financial challenges and seeks to regain market traction.
Outlook, Risks, and Final Insight
The outlook for ANG Lifesciences hinges on its ability to stabilize operations and improve financial performance. Key strengths include a strong promoter holding that can provide strategic direction and a low P/BV ratio that may attract value-focused investors. However, significant risks include declining revenues, negative profitability, and a high debt burden which could limit operational flexibility. The company’s reliance on debt financing poses a threat, especially if revenue challenges persist. Additionally, the rising cash conversion cycle indicates potential liquidity pressures that could impact operational capabilities. In a scenario where the company successfully implements cost controls and enhances product offerings, there may be a pathway to recovery. Conversely, failure to address these issues could lead to further financial deterioration and diminished investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of ANG Lifesciences India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.81 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71.56 | 58.39 | 45.17 | 31.88 | 50.61 | 29.58 | 17.10 | 34.08 | 16.18 | 32.16 | 23.91 | 17.67 | 24.53 |
| Expenses | 60.28 | 49.15 | 43.03 | 43.48 | 44.94 | 28.26 | 18.82 | 30.23 | 18.11 | 29.70 | 25.89 | 18.03 | 22.67 |
| Operating Profit | 11.28 | 9.24 | 2.14 | -11.60 | 5.67 | 1.32 | -1.72 | 3.85 | -1.93 | 2.46 | -1.98 | -0.36 | 1.86 |
| OPM % | 15.76% | 15.82% | 4.74% | -36.39% | 11.20% | 4.46% | -10.06% | 11.30% | -11.93% | 7.65% | -8.28% | -2.04% | 7.58% |
| Other Income | 0.12 | 0.20 | 0.32 | 9.20 | 0.34 | 0.33 | -0.09 | -1.49 | 1.36 | 0.36 | -0.03 | 0.75 | 0.17 |
| Interest | 3.17 | 3.20 | 2.84 | 1.11 | 1.94 | 1.96 | 1.99 | 3.44 | 1.67 | 1.87 | 1.71 | 2.05 | 1.61 |
| Depreciation | 1.88 | 1.90 | 1.92 | 2.82 | 1.94 | 1.97 | 2.02 | 1.83 | 1.51 | 1.62 | 1.84 | 1.30 | 1.45 |
| Profit before tax | 6.35 | 4.34 | -2.30 | -6.33 | 2.13 | -2.28 | -5.82 | -2.91 | -3.75 | -0.67 | -5.56 | -2.96 | -1.03 |
| Tax % | 47.24% | 39.63% | -30.43% | -20.54% | 25.35% | -10.09% | -20.96% | 23.71% | -26.13% | 61.19% | -17.99% | -34.46% | -23.30% |
| Net Profit | 3.34 | 2.62 | -1.60 | -5.03 | 1.60 | -2.05 | -4.59 | -3.60 | -2.77 | -1.07 | -4.57 | -1.94 | -0.79 |
| EPS in Rs | 2.57 | 2.02 | -1.23 | -3.85 | 1.23 | -1.57 | -3.52 | -2.76 | -2.12 | -0.82 | -3.50 | -1.49 | -0.60 |
Last Updated: August 19, 2025, 11:45 pm
Below is a detailed analysis of the quarterly data for ANG Lifesciences India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 24.53 Cr.. The value appears strong and on an upward trend. It has increased from 17.67 Cr. (Mar 2025) to 24.53 Cr., marking an increase of 6.86 Cr..
- For Expenses, as of Jun 2025, the value is 22.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.03 Cr. (Mar 2025) to 22.67 Cr., marking an increase of 4.64 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.86 Cr.. The value appears strong and on an upward trend. It has increased from -0.36 Cr. (Mar 2025) to 1.86 Cr., marking an increase of 2.22 Cr..
- For OPM %, as of Jun 2025, the value is 7.58%. The value appears strong and on an upward trend. It has increased from -2.04% (Mar 2025) to 7.58%, marking an increase of 9.62%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.75 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.58 Cr..
- For Interest, as of Jun 2025, the value is 1.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.05 Cr. (Mar 2025) to 1.61 Cr., marking a decrease of 0.44 Cr..
- For Depreciation, as of Jun 2025, the value is 1.45 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.30 Cr. (Mar 2025) to 1.45 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.03 Cr.. The value appears strong and on an upward trend. It has increased from -2.96 Cr. (Mar 2025) to -1.03 Cr., marking an increase of 1.93 Cr..
- For Tax %, as of Jun 2025, the value is -23.30%. The value appears to be increasing, which may not be favorable. It has increased from -34.46% (Mar 2025) to -23.30%, marking an increase of 11.16%.
- For Net Profit, as of Jun 2025, the value is -0.79 Cr.. The value appears strong and on an upward trend. It has increased from -1.94 Cr. (Mar 2025) to -0.79 Cr., marking an increase of 1.15 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.60. The value appears strong and on an upward trend. It has increased from -1.49 (Mar 2025) to -0.60, marking an increase of 0.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 98.27 |
| Expenses | 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 96.29 |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.98 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 2.01% |
| Other Income | 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.25 |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 7.24 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.21 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.22 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| Net Profit | 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.37 |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.41 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 110.53% | 312.50% | 70.91% | 31.91% | 51.88% | 7.96% | 18.85% | 447.72% | -101.66% | -1210.61% | -19.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 201.97% | -241.59% | -38.99% | 19.97% | -43.92% | 10.89% | 428.87% | -549.39% | -1108.94% | 1191.07% |
ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -45% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:16 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.14 | -7.03 | -7.04 | -7.51 | -10.12 | -10.26 | -8.40 | -27.07 | 4.55 | -43.89 | -49.81 | -71.60 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Revenue From Operations / Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 |
| PBDIT / Share (Rs.) | -0.19 | 7.92 | 18.27 | 65.87 |
| PBIT / Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 |
| PBT / Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 |
| Net Profit / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| PBDIT Margin (%) | -0.27 | 7.07 | 10.84 | 19.27 |
| PBIT Margin (%) | -7.55 | 1.34 | 6.59 | 17.61 |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| Return on Networth / Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 |
| Return on Capital Employeed (%) | -8.14 | 2.01 | 12.35 | 50.02 |
| Return On Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 |
| Long Term Debt / Equity (X) | 0.29 | 0.18 | 0.23 | 0.25 |
| Total Debt / Equity (X) | 1.26 | 0.90 | 0.81 | 0.91 |
| Asset Turnover Ratio (%) | 0.39 | 0.55 | 0.77 | 0.00 |
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 |
| Quick Ratio (X) | 0.77 | 0.90 | 0.85 | 0.93 |
| Inventory Turnover Ratio (X) | 1.25 | 2.14 | 3.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 |
| Interest Coverage Ratio (X) | -0.02 | 0.94 | 2.01 | 7.67 |
| Interest Coverage Ratio (Post Tax) (X) | -0.42 | 0.23 | 0.97 | 5.53 |
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 |
| EV / Net Operating Revenue (X) | 1.15 | 0.83 | 0.74 | 0.88 |
| EV / EBITDA (X) | -416.21 | 11.83 | 6.84 | 4.59 |
| MarketCap / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 |
| Price / BV (X) | 0.46 | 0.77 | 1.15 | 2.90 |
| Price / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| EarningsYield | -0.41 | -0.17 | 0.00 | 0.16 |
After reviewing the key financial ratios for ANG Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 3. It has decreased from -1.36 (Mar 24) to -4.33, marking a decrease of 2.97.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.10. It has decreased from 111.89 (Mar 24) to 71.10, marking a decrease of 40.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 2. It has decreased from 7.92 (Mar 24) to -0.19, marking a decrease of 8.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.37. This value is below the healthy minimum of 0. It has decreased from 1.51 (Mar 24) to -5.37, marking a decrease of 6.88.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.03. This value is below the healthy minimum of 0. It has decreased from -8.20 (Mar 24) to -12.03, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For PBDIT Margin (%), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 10. It has decreased from 7.07 (Mar 24) to -0.27, marking a decrease of 7.34.
- For PBIT Margin (%), as of Mar 25, the value is -7.55. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -7.55, marking a decrease of 8.89.
- For PBT Margin (%), as of Mar 25, the value is -16.91. This value is below the healthy minimum of 10. It has decreased from -7.33 (Mar 24) to -16.91, marking a decrease of 9.58.
- For Net Profit Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 5. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 8. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is -19.40. This value is below the healthy minimum of 15. It has decreased from -13.29 (Mar 24) to -19.40, marking a decrease of 6.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.14. This value is below the healthy minimum of 10. It has decreased from 2.01 (Mar 24) to -8.14, marking a decrease of 10.15.
- For Return On Assets (%), as of Mar 25, the value is -5.40. This value is below the healthy minimum of 5. It has decreased from -4.18 (Mar 24) to -5.40, marking a decrease of 1.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.26. This value exceeds the healthy maximum of 1. It has increased from 0.90 (Mar 24) to 1.26, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.55 (Mar 24) to 0.39, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 1.5. It has decreased from 1.24 (Mar 24) to 1.15, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.77, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 4. It has decreased from 2.14 (Mar 24) to 1.25, marking a decrease of 0.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 3. It has decreased from 0.94 (Mar 24) to -0.02, marking a decrease of 0.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.42. This value is below the healthy minimum of 3. It has decreased from 0.23 (Mar 24) to -0.42, marking a decrease of 0.65.
- For Enterprise Value (Cr.), as of Mar 25, the value is 106.47. It has decreased from 122.38 (Mar 24) to 106.47, marking a decrease of 15.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 1.15, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is -416.21. This value is below the healthy minimum of 5. It has decreased from 11.83 (Mar 24) to -416.21, marking a decrease of 428.04.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.46, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.41. This value is below the healthy minimum of 5. It has decreased from -0.17 (Mar 24) to -0.41, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
- Net Profit Margin: -13.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.14% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.4% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 55.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Darbara Complex, Amritsar Punjab 143001 | cs@anglifesciences.com http://www.anglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mr. Sukhpal Singh | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mrs. Chetna | Independent Director |

